D. E. Shaw & Co., Inc. Biomarin Pharmaceutical Inc Transaction History

D. E. Shaw & Co., Inc.

$98.6 Billion
Q2 2024

A detailed history of D. E. Shaw & Co., Inc. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 268,374 shares of BMRN stock, worth $18.9 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

268,374

Previous 422,298 36.45%

Holding current value

$18.9 Million

Previous $36.9 Million 40.09%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$74.43 - $92.22 $11.5 Million - $14.2 Million	-153,924 Reduced 36.45%	268,374 $22.1 Million
Q1 2024 May 15, 2024	BUY	$83.81 - $99.0 $19.3 Million - $22.8 Million	229,846 Added 119.43%	422,298 $36.9 Million
Q4 2023 Feb 14, 2024	SELL	$76.22 - $98.51 $25.3 Million - $32.7 Million	-331,687 Reduced 63.28%	192,452 $18.6 Million
Q3 2023 Nov 14, 2023	SELL	$85.07 - $94.48 $32.8 Million - $36.4 Million	-385,678 Reduced 42.39%	524,139 $46.4 Million
Q2 2023 Aug 14, 2023	SELL	$86.68 - $100.3 $19.2 Million - $22.2 Million	-221,222 Reduced 19.56%	909,817 $78.9 Million
Q1 2023 May 15, 2023	SELL	$87.74 - $117.27 $24.4 Million - $32.6 Million	-278,085 Reduced 19.73%	1,131,039 $110 Million
Q4 2022 Feb 14, 2023	BUY	$80.93 - $108.63 $31.6 Million - $42.4 Million	389,867 Added 38.25%	1,409,124 $146 Million
Q3 2022 Nov 14, 2022	SELL	$82.16 - $96.94 $2.4 Million - $2.84 Million	-29,260 Reduced 2.79%	1,019,257 $86.4 Million
Q2 2022 Aug 15, 2022	BUY	$71.48 - $86.85 $25.8 Million - $31.3 Million	360,411 Added 52.38%	1,048,517 $86.9 Million
Q1 2022 May 16, 2022	SELL	$74.28 - $92.69 $17.4 Million - $21.7 Million	-233,616 Reduced 25.35%	688,106 $53.1 Million
Q4 2021 Feb 14, 2022	BUY	$71.72 - $91.47 $10.5 Million - $13.4 Million	146,110 Added 18.84%	921,722 $81.4 Million
Q3 2021 Nov 15, 2021	BUY	$74.77 - $85.47 $19 Million - $21.8 Million	254,731 Added 48.9%	775,612 $59.9 Million
Q2 2021 Aug 16, 2021	SELL	$75.51 - $84.79 $4.35 Million - $4.88 Million	-57,605 Reduced 9.96%	520,881 $43.5 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $752,904 - $913,701	-10,075 Reduced 1.71%	578,486 $43.7 Million
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $38.3 Million - $47.6 Million	527,231 Added 859.66%	588,561 $51.6 Million
Q3 2020 Nov 16, 2020	BUY	$71.87 - $131.03 $4.08 Million - $7.44 Million	56,804 Added 1255.06%	61,330 $4.67 Million
Q2 2020 Aug 14, 2020	SELL	$79.55 - $124.22 $7.39 Million - $11.5 Million	-92,959 Reduced 95.36%	4,526 $558,000
Q1 2020 May 15, 2020	SELL	$71.37 - $96.85 $12.7 Million - $17.3 Million	-178,603 Reduced 64.69%	97,485 $8.24 Million
Q4 2019 Feb 14, 2020	BUY	$64.27 - $86.37 $8.55 Million - $11.5 Million	132,987 Added 92.93%	276,088 $23.3 Million
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $3.82 Million - $4.82 Million	56,666 Added 65.56%	143,101 $9.65 Million
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $2.08 Million - $2.43 Million	-25,835 Reduced 23.01%	86,435 $7.4 Million
Q1 2019 May 15, 2019	SELL	$84.2 - $98.62 $10.4 Million - $12.2 Million	-123,499 Reduced 52.38%	112,270 $9.97 Million
Q4 2018 Feb 14, 2019	BUY	$80.14 - $106.07 $11 Million - $14.6 Million	137,558 Added 140.06%	235,769 $20.1 Million
Q3 2018 Nov 14, 2018	BUY	$93.92 - $105.72 $7.66 Million - $8.62 Million	81,567 Added 490.07%	98,211 $9.52 Million
Q2 2018 Aug 14, 2018	SELL	$76.01 - $99.03 $5.25 Million - $6.84 Million	-69,066 Reduced 80.58%	16,644 $1.57 Million
Q1 2018 May 15, 2018	SELL	$77.67 - $92.63 $6.06 Million - $7.22 Million	-77,964 Reduced 47.63%	85,710 $6.95 Million
Q4 2017 Feb 14, 2018	BUY	$80.76 - $95.13 $5.81 Million - $6.84 Million	71,882 Added 78.31%	163,674 $14.6 Million
Q3 2017 Nov 14, 2017	BUY	$80.6 - $94.95 $7.4 Million - $8.72 Million	91,792	91,792 $8.54 Million

Others Institutions Holding BMRN

# of Institutions

632

Shares Held

185M

Call Options Held

1.63M

Put Options Held

1.2M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account